Literature DB >> 26715808

Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.

Ting-Ting Li1, Hao Liu1, Feng-Ping Li1, Yan-Feng Hu1, Ting-Yu Mou1, Tian Lin1, Jiang Yu1, Lei Zheng1, Guo-Xin Li1.   

Abstract

AIM: To evaluate the epithelial-to-mesenchymal transition (EMT) of circulating tumor cells (CTCs) in gastric cancer patients.
METHODS: We detected tumor cells for expression of four epithelial (E(+)) transcripts (keratins 8, 18, and 19 and epithelial cell adhesion molecule) and two mesenchymal (M(+)) transcripts (Vimentin and Twist) by a quantifiable, dual-colorimetric RNA-in situ hybridization assay. Between July 2014 and October 2014, 44 patients with gastric cancer were recruited for CTC evaluation. Blood samples were obtained from selected patients during the treatment course [before surgery, after surgery and at the 6(th) cycle of XELOX based chemotherapy (about 6 mo postoperatively)].
RESULTS: We found the EMT phenomenon in which there were a few biphenotypic E(+)/M(+) cells in primary human gastric cancer specimens. Of the 44 patients, the presence of CTCs was reported in 35 (79.5%) patients at baseline. Five types of cells including from exclusively E(+) CTCs to intermediate CTCs and exclusively M(+) CTCs were identified (4 patients with M(+) CTCs and 10 patients with M(+) or M(+) > E(+) CTCs). Further, a chemotherapy patient having progressive disease showed a proportional increase of mesenchymal CTCs in the post-treatment blood specimens. We used NCI-N87 cells to analyze the linearity and sensitivity of CanPatrol(TM) system and the correlation coefficient (R(2)) was 0.999.
CONCLUSION: The findings suggest that the EMT phenomenon was both in a few cells of primary tumors and abundantly in CTCs from the blood of gastric cancer patients, which might be used to monitor therapy response.

Entities:  

Keywords:  Chemotherapy; Circulating tumor cells; Epithelial-to-mesenchymal transition; Gastric cancer; Therapy response

Mesh:

Substances:

Year:  2015        PMID: 26715808      PMCID: PMC4679757          DOI: 10.3748/wjg.v21.i47.13259

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions.

Authors:  Shiyang Wu; Zhiming Liu; Suyan Liu; Li Lin; Weiwei Yang; Jiasen Xu
Journal:  Clin Chem Lab Med       Date:  2014-02       Impact factor: 3.694

Review 2.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

Review 3.  Circulating tumor DNA as a liquid biopsy for cancer.

Authors:  Ellen Heitzer; Peter Ulz; Jochen B Geigl
Journal:  Clin Chem       Date:  2014-11-11       Impact factor: 8.327

Review 4.  Circulating tumor cells: liquid biopsy of cancer.

Authors:  Catherine Alix-Panabières; Klaus Pantel
Journal:  Clin Chem       Date:  2012-09-26       Impact factor: 8.327

5.  Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy.

Authors:  Michal Mego; Sendurai A Mani; Bang-Ning Lee; Changping Li; Kurt W Evans; Evan N Cohen; Hui Gao; Summer A Jackson; Antonio Giordano; Gabriel N Hortobagyi; Massimo Cristofanilli; Anthony Lucci; James M Reuben
Journal:  Int J Cancer       Date:  2011-04-27       Impact factor: 7.396

6.  Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

Authors:  Howard I Scher; Xiaoyu Jia; Johann S de Bono; Martin Fleisher; Kenneth J Pienta; Derek Raghavan; Glenn Heller
Journal:  Lancet Oncol       Date:  2009-02-11       Impact factor: 41.316

Review 7.  Tumor cell dissemination: emerging biological insights from animal models and cancer patients.

Authors:  Yibin Kang; Klaus Pantel
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

8.  Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy.

Authors:  Janet M Pavese; Raymond C Bergan
Journal:  Cancer Lett       Date:  2014-07-10       Impact factor: 8.679

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more
  34 in total

1.  Diagnostic Value of Different Phenotype Circulating Tumor Cells in Hepatocellular Carcinoma.

Authors:  Yuan Cheng; Lei Luo; Juqiang Zhang; Mantian Zhou; Yujun Tang; Guolin He; Yishi Lu; Zhong Wang; MingXin Pan
Journal:  J Gastrointest Surg       Date:  2019-02-25       Impact factor: 3.452

Review 2.  Epithelial-mesenchymal plasticity in circulating tumor cells.

Authors:  Catherine Alix-Panabières; Sonja Mader; Klaus Pantel
Journal:  J Mol Med (Berl)       Date:  2016-12-24       Impact factor: 4.599

3.  Epithelial-to-mesenchymal transition of circulating tumor cells and CD133 expression on predicting prognosis of thyroid cancer patients.

Authors:  Deyu Li; Na Li; Ying Ding
Journal:  Mol Clin Oncol       Date:  2022-08-01

4.  Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case.

Authors:  Shoujie Chai; Carmen Ruiz-Velasco; Amin Naghdloo; Milind Pore; Mohan Singh; Nicholas Matsumoto; Anand Kolatkar; Liya Xu; Stephanie Shishido; Ana Aparicio; Amado J Zurita; James Hicks; Peter Kuhn
Journal:  NPJ Precis Oncol       Date:  2022-06-21

Review 5.  Epithelial-Mesenchymal Plasticity in Tumor Immune Evasion.

Authors:  Riley D Z Mullins; Ananya Pal; Thomas F Barrett; Molly E Heft Neal; Sidharth V Puram
Journal:  Cancer Res       Date:  2022-07-05       Impact factor: 13.312

6.  Prognostic Significance of Circulating Tumor Cells with Mesenchymal Phenotypes in Patients with Gastric Cancer: A Prospective Study.

Authors:  Yui Ishiguro; Hideyasu Sakihama; Tadashi Yoshida; Nobuki Ichikawa; Shigenori Homma; Moto Fukai; Hideki Kawamura; Norihiko Takahashi; Akinobu Taketomi
Journal:  Ann Surg Oncol       Date:  2020-08-07       Impact factor: 5.344

7.  Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition: Influence on Prognosis in Cytokeratin 19-Positive Hepatocellular Carcinoma.

Authors:  Qian Zhang; Wanting Xing; Jie Zhang; Junwen Hu; Lunan Qi; Bangde Xiang
Journal:  Onco Targets Ther       Date:  2021-03-02       Impact factor: 4.147

8.  Prognostic Role of the Circulating Tumor Cells Detected by Cytological Methods in Gastric Cancer: A Meta-Analysis.

Authors:  Kun Zou; Shuailong Yang; Liang Zheng; Shuyi Wang; Bin Xiong
Journal:  Biomed Res Int       Date:  2016-10-24       Impact factor: 3.411

9.  Association of Preoperative NANOG-Positive Circulating Tumor Cell Levels With Recurrence of Hepatocellular Carcinoma.

Authors:  Yongrong Lei; Xishu Wang; Heng Sun; Yuna Fu; Yichen Tian; Ludi Yang; Jianhua Wang; Feng Xia
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 6.244

Review 10.  The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells.

Authors:  Alexandra C Kölbl; Udo Jeschke; Ulrich Andergassen
Journal:  Int J Mol Sci       Date:  2016-08-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.